Express News | Immunic-Files Prospectus Supplement for Sale $80.0 Mln of Shares of Common Stock, May Offer & Sell From Time to Time Through Leerink Partners
Express News | Immunic Inc -Had Previously Entered Into Sales Agreement With Leerink Partners Dated May 2, 2022 Relating to Shares of Common Stock
When Will Immunic, Inc. (NASDAQ:IMUX) Breakeven?
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day | NASDAQ:IMUX
Immunic to Participate in Industry and Scientific Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
Express News | Immunic Inc Raises Size of Mixed Shelf Offering to $412.3 Mln From $250 Mln - SEC Filing
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Immunic | 10-Q: Quarterly report
Express News | Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic: Q1 Earnings Snapshot
Express News | Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Express News | Immunic Inc - Expects to Be Able to Fund Its Operations Into Q3 of 2025.
Express News | Immunic Q1 Operating Expenses USD 23.881 Million
Express News | Immunic Q1 Income From Operations USD -23.881 Million
Express News | Immunic Q1 Basic EPS USD -0.3
Express News | Immunic Q1 Net Income USD -29.584 Million
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
Immunic 1Q Loss/Shr 30c >IMUX
Immunic 1Q Loss/Shr 30c >IMUX
Immunic 1Q Loss $29.6M >IMUX
Immunic 1Q Loss $29.6M >IMUX
No Data